Skip to main content
Top

Current Treatment Options in Oncology

Issue 4/2024

Content (10 Articles)

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

Sietske C. M. W. van Nassau, Guus M. Bol, Frederieke H. van der Baan, Jeanine M. L. Roodhart, Geraldine R. Vink, Cornelis J. A. Punt, Anne M. May, Miriam Koopman, Jeroen W. G. Derksen

Open Access Rectal Cancer

Treatment Options for Distal Rectal Cancer in the Era of Organ Preservation

Chen Wang, Xiaoliang Liu, Weiping Wang, Zheng Miao, Xiaoyan Li, Dingchao Liu, Ke Hu

A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies

Vincenzo Costanzo, Yashwant Kumar Ratre, Emanuela Andretta, Rakesh Acharya, L. V. K. S. Bhaskar, Henu Kumar Verma

Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?

Suhaib Khateeb, Ludimila Cavalcante, Noor Alnairat, Meghana Singh, Ibrahim Halil Sahin, Azhar Saeed, Anwaar Saeed

Open Access Breast Cancer

Ovarian Suppression: Early Menopause and Late Effects

Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone, Silvia Ottonello, Piero Fregatti, Cynthia Villarreal-Garza, Jyoti Bajpai, Hee Jeong Kim, Silvia Puglisi, Evandro de Azambuja, Matteo Lambertini

Update on Dosing and Fractionation for Neoadjuvant Radiotherapy for Localized Soft Tissue Sarcoma

Siyer Roohani, Lisette M. Wiltink, David Kaul, Mateusz Jacek Spałek, Rick L. Haas

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine